September 11, 2017 10:08 AM EDT
R&D

Re­gen­eron, Sanofi post good PhI­II asth­ma da­ta for Dupix­ent — but it’s los­ing its ha­lo

John Carroll

Editor & Founder

Just days af­ter As­traZeneca and Am­gen man­aged to catch an­a­lysts sleep­ing with a promis­ing new asth­ma drug called teze­pelum­ab, Re­gen­eron and Sanofi are com­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times